<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04114825</url>
  </required_header>
  <id_info>
    <org_study_id>RhoVac-002</org_study_id>
    <nct_id>NCT04114825</nct_id>
  </id_info>
  <brief_title>Study of RV001V in Biochemical Failure Following Curatively Intended Therapy For Localized Prostate Cancer</brief_title>
  <acronym>BRaVac</acronym>
  <official_title>A Phase 2, Double-Blind, Placebo Controlled Study of RV001V in Men With Biochemical Failure Following Curatively Intended Therapy For Localized Prostate Cancer (BRaVac)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RhoVac APS</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RhoVac APS</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase II trial will enroll approximately 180 adult male patients with an earlier
      histologic diagnosis of prostatic adenocarcinoma and a biochemical recurrence (BCR) within 3
      years of radical prostatectomy (RP) or definitive RT and no distant metastasis or
      locoregional recurrence. The trial is a randomized placebo-controlled double-blind study of a
      peptide cancer vaccine (RV001V).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 19, 2019</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to PSA progression</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Time to PSA progression is defined as the time from randomization to doubling of PSA from the baseline value. The time to doubling will be estimated from a log-linear regression of PSA values.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety by frequency and severity of adverse events (AEs)</measure>
    <time_frame>Up to 16 months</time_frame>
    <description>The numbers and proportions of patients with any treatment-emergent adverse event (TEAE), and any serious TEAE will be summarized</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to initiation of a subsequent antineoplastic therapy</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients showing a PSA response from baseline</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival (DFS)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>time from randomization to documented clinical recurrence (distant or local), or death from any cause, censoring at date of last follow-up (FU)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Prostate Cancer Recurrent</condition>
  <arm_group>
    <arm_group_label>RV001V</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Total of 12 SC vaccinations with RV001V. The first 6 vaccinations (priming period) will be given every 2 weeks, and then the following 5 vaccinations (7 through 11) will be administered with 4 weeks between each vaccination (Maintenance period), and the last vaccination (12th) will be administered 6 months following the 11th vaccination (boosting injection).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Total of 12 SC vaccinations with placebo. The first 6 vaccinations (priming period) will be given every 2 weeks, and then the following 5 vaccinations (7 through 11) will be administered with 4 weeks between each vaccination (Maintenance period), and the last vaccination (12th) will be administered 6 months following the 11th vaccination (boosting injection).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>RV001V</intervention_name>
    <description>RV001V consists of the peptide RV001 and the adjuvant Montanide ISA 51. RV001 Vaccine 0.1 mg/mL (RV001V).</description>
    <arm_group_label>RV001V</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo consist of the vaccine vehicle and the adjuvant Montanide ISA 51. Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:

          -  Biochemical recurrence (BCR) within 3 years of radical prostatectomy (RP) or
             definitive RT and no distant metastasis by standard CT imaging and bone scintigraphy,
             or locoregional recurrence (including lymph nodes) assessed by CT or multi-parametric
             magnetic resonance imaging (MRI) and confirmed with negative biopsy in case of prior
             RT.

          -  In case of BCR after RP all the following criteria should apply: a. PSA ≥0.2 ng/mL, b.
             PSA Doubling Time (PSADT) &gt;3 months and &lt;12 months, c. History of Gleason 7 (4 + 3) or
             higher.

          -  In case of BCR after RT all the following criteria should apply: a. PSA &gt;nadir + 2
             ng/mL, b. PSADT &gt;3 months and &lt;12 months, c.History of Gleason score of 7 (4 + 3) or
             higher

          -  ECOG performance status ≤2.

          -  Laboratory values obtained ≤30 days prior to first vaccination: Hemoglobin ≥5.6
             mmol/L; Absolute granulocyte count ≥1.5 x 109 /L, Platelets ≥100 x 109 /L., Total
             bilirubin ≤1.5 x upper limit of normal (ULN).

          -  Creatinine ≤1.5 x ULN.

          -  Alanine aminotransferase (ALT), aspartate aminotransferase (AST) and alkaline
             phosphatase (ALP) ≤2.5 x ULN.

        Main Exclusion Criteria:

          -  Patients who are receiving androgen-deprivation therapy or considered a candidate for
             immediate anti-androgen deprivation therapy (ADT) as judged by the investigator.

          -  Patients who have received prior ADT are not eligible with the exception of those that
             received ADT ≤36 months in duration and ≥9 months before randomization and
             administered only in the neoadjuvant/adjuvant setting.

          -  Patient is planned for salvage therapy with RT or radical prostatectomy.

          -  Castrate level of serum testosterone &lt;50 ng/dL at screening.

          -  PSA &gt;10 ng/mL.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Klaus Brasso, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Steven Glazer, MD</last_name>
    <phone>+45 25674434</phone>
    <email>sgl@rhovac.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Malene Weis, PharmD</last_name>
    <phone>+45 53542818</phone>
    <email>mw@rhovac.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chesapeake Urology Research Associates</name>
      <address>
        <city>Towson</city>
        <state>Maryland</state>
        <zip>21204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Levin, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Centers of Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89169</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicholas Vogelzang, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Carolina Urologic Research Center</name>
      <address>
        <city>Myrtle Beach</city>
        <state>South Carolina</state>
        <zip>29572</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Neal Shore, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gent University Hospital</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolaas Lumen, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Liège</name>
      <address>
        <city>Liège</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Waltregny, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Erasme</name>
      <address>
        <city>Liège</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thierry Roumeguere, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aalborg University, Departmen of Urology</name>
      <address>
        <city>Aalborg</city>
        <zip>9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Niels Christian Langkilde, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aarhus University Hospital, Department of Urology</name>
      <address>
        <city>Aarhus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Borre, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet, Copenhagen Prostate Cancer Center</name>
      <address>
        <city>Copenhagen</city>
        <zip>2200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Klaus Brasso, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Herlev &amp; Gentofte Hospital, Department of Urology</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Andersen, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Urinvejskirurgisk afdeling, Hospitalsenheden Vest</name>
      <address>
        <city>Holstebro</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jørgen Bjerggard Jensen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital, Deparment of Urology</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mads Hvid Aaberg Poulsen, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Docrates Cancer Center</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jorma Sormunen, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Meilahti Tower Hospital</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antti Rairnikko, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oulu University Hospital</name>
      <address>
        <city>Oulu</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hanna Dr Ronkainen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seinajoki Central Hospital</name>
      <address>
        <city>Seinäjoki</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Timo Marttila, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tampere University Hospital</name>
      <address>
        <city>Tampere</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Teuvo Tammela, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Turku University Hospital</name>
      <address>
        <city>Turku</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Boström</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Dresden</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carsten Grüllich, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Urologicum Duisburg</name>
      <address>
        <city>Duisburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eva Hellmis, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Erlangen</name>
      <address>
        <city>Erlangen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Goebell, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Urologische Praxis Dr. Wolfgang Warnack</name>
      <address>
        <city>Hagenow</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wolfgang Warnack, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Saarland</name>
      <address>
        <city>Homburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heinzelbecker, PD Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Studienpraxis Urologie</name>
      <address>
        <city>Nürtingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tilman Todenhöfer, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wissenschaftskontor Nord GmbH &amp; Co. KG</name>
      <address>
        <city>Rostock</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Hübner, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Urologische Praxis Dr. Ewgeni Rosengrün</name>
      <address>
        <city>Schwerin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ewgeni Rosengrün, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Tuebingen</name>
      <address>
        <city>Tübingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arnulf Stenzl, Prof. Dr.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>September 28, 2019</study_first_submitted>
  <study_first_submitted_qc>October 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 3, 2019</study_first_posted>
  <last_update_submitted>June 13, 2020</last_update_submitted>
  <last_update_submitted_qc>June 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Biochemical relapse</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

